Cargando…

Evodiamine Mitigates Cellular Growth and Promotes Apoptosis by Targeting the c-Met Pathway in Prostate Cancer Cells

Evodiamine (EVO) is an indoloquinazoline alkaloid that exerts its various anti-oncogenic actions by blocking phosphatidylinositol-3-kinase/protein kinase B (PI3K/Akt), mitogen-activated protein kinase (MAPK), c-Met, and nuclear factor kappa B (NF-κB) signaling pathways, thus leading to apoptosis of...

Descripción completa

Detalles Bibliográficos
Autores principales: Hwang, Sun Tae, Um, Jae-Young, Chinnathambi, Arunachalam, Alharbi, Sulaiman Ali, Narula, Acharan S., Namjoshi, Ojas A., Blough, Bruce E., Ahn, Kwang Seok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144730/
https://www.ncbi.nlm.nih.gov/pubmed/32183146
http://dx.doi.org/10.3390/molecules25061320
_version_ 1783519877625020416
author Hwang, Sun Tae
Um, Jae-Young
Chinnathambi, Arunachalam
Alharbi, Sulaiman Ali
Narula, Acharan S.
Namjoshi, Ojas A.
Blough, Bruce E.
Ahn, Kwang Seok
author_facet Hwang, Sun Tae
Um, Jae-Young
Chinnathambi, Arunachalam
Alharbi, Sulaiman Ali
Narula, Acharan S.
Namjoshi, Ojas A.
Blough, Bruce E.
Ahn, Kwang Seok
author_sort Hwang, Sun Tae
collection PubMed
description Evodiamine (EVO) is an indoloquinazoline alkaloid that exerts its various anti-oncogenic actions by blocking phosphatidylinositol-3-kinase/protein kinase B (PI3K/Akt), mitogen-activated protein kinase (MAPK), c-Met, and nuclear factor kappa B (NF-κB) signaling pathways, thus leading to apoptosis of tumor cells. We investigated the ability of EVO to affect hepatocyte growth factor (HGF)-induced c-Met/Src/STAT3 activation cascades in castration-resistant prostate cancer (CRPC). First, we noted that EVO showed cytotoxicity and anti-proliferation activities in PC-3 and DU145 cells. Next, we found that EVO markedly inhibited HGF-induced c-Met/Src/STAT3 phosphorylation and impaired the nuclear translocation of STAT3 protein. Then, we noted that EVO arrested the cell cycle, caused apoptosis, and downregulated the expression of various carcinogenic markers such as B-cell lymphoma 2 (Bcl-2), B-cell lymphoma-extra large (Bcl-xL), cyclin D1, cyclooxygenase 2 (COX-2), survivin, vascular endothelial growth factor (VEGF), and matrix metallopeptidases 9 (MMP-9). Moreover, it was observed that in cPC-3 and DU145 cells transfected with c-Met small interfering RNA (siRNA), Src/STAT3 activation was also mitigated and led to a decrease in EVO-induced apoptotic cell death. According to our results, EVO can abrogate the activation of the c-Met/Src/STAT3 signaling axis and thus plays a role as a robust suppressor of tumor cell survival, proliferation, and angiogenesis.
format Online
Article
Text
id pubmed-7144730
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71447302020-04-15 Evodiamine Mitigates Cellular Growth and Promotes Apoptosis by Targeting the c-Met Pathway in Prostate Cancer Cells Hwang, Sun Tae Um, Jae-Young Chinnathambi, Arunachalam Alharbi, Sulaiman Ali Narula, Acharan S. Namjoshi, Ojas A. Blough, Bruce E. Ahn, Kwang Seok Molecules Article Evodiamine (EVO) is an indoloquinazoline alkaloid that exerts its various anti-oncogenic actions by blocking phosphatidylinositol-3-kinase/protein kinase B (PI3K/Akt), mitogen-activated protein kinase (MAPK), c-Met, and nuclear factor kappa B (NF-κB) signaling pathways, thus leading to apoptosis of tumor cells. We investigated the ability of EVO to affect hepatocyte growth factor (HGF)-induced c-Met/Src/STAT3 activation cascades in castration-resistant prostate cancer (CRPC). First, we noted that EVO showed cytotoxicity and anti-proliferation activities in PC-3 and DU145 cells. Next, we found that EVO markedly inhibited HGF-induced c-Met/Src/STAT3 phosphorylation and impaired the nuclear translocation of STAT3 protein. Then, we noted that EVO arrested the cell cycle, caused apoptosis, and downregulated the expression of various carcinogenic markers such as B-cell lymphoma 2 (Bcl-2), B-cell lymphoma-extra large (Bcl-xL), cyclin D1, cyclooxygenase 2 (COX-2), survivin, vascular endothelial growth factor (VEGF), and matrix metallopeptidases 9 (MMP-9). Moreover, it was observed that in cPC-3 and DU145 cells transfected with c-Met small interfering RNA (siRNA), Src/STAT3 activation was also mitigated and led to a decrease in EVO-induced apoptotic cell death. According to our results, EVO can abrogate the activation of the c-Met/Src/STAT3 signaling axis and thus plays a role as a robust suppressor of tumor cell survival, proliferation, and angiogenesis. MDPI 2020-03-13 /pmc/articles/PMC7144730/ /pubmed/32183146 http://dx.doi.org/10.3390/molecules25061320 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hwang, Sun Tae
Um, Jae-Young
Chinnathambi, Arunachalam
Alharbi, Sulaiman Ali
Narula, Acharan S.
Namjoshi, Ojas A.
Blough, Bruce E.
Ahn, Kwang Seok
Evodiamine Mitigates Cellular Growth and Promotes Apoptosis by Targeting the c-Met Pathway in Prostate Cancer Cells
title Evodiamine Mitigates Cellular Growth and Promotes Apoptosis by Targeting the c-Met Pathway in Prostate Cancer Cells
title_full Evodiamine Mitigates Cellular Growth and Promotes Apoptosis by Targeting the c-Met Pathway in Prostate Cancer Cells
title_fullStr Evodiamine Mitigates Cellular Growth and Promotes Apoptosis by Targeting the c-Met Pathway in Prostate Cancer Cells
title_full_unstemmed Evodiamine Mitigates Cellular Growth and Promotes Apoptosis by Targeting the c-Met Pathway in Prostate Cancer Cells
title_short Evodiamine Mitigates Cellular Growth and Promotes Apoptosis by Targeting the c-Met Pathway in Prostate Cancer Cells
title_sort evodiamine mitigates cellular growth and promotes apoptosis by targeting the c-met pathway in prostate cancer cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144730/
https://www.ncbi.nlm.nih.gov/pubmed/32183146
http://dx.doi.org/10.3390/molecules25061320
work_keys_str_mv AT hwangsuntae evodiaminemitigatescellulargrowthandpromotesapoptosisbytargetingthecmetpathwayinprostatecancercells
AT umjaeyoung evodiaminemitigatescellulargrowthandpromotesapoptosisbytargetingthecmetpathwayinprostatecancercells
AT chinnathambiarunachalam evodiaminemitigatescellulargrowthandpromotesapoptosisbytargetingthecmetpathwayinprostatecancercells
AT alharbisulaimanali evodiaminemitigatescellulargrowthandpromotesapoptosisbytargetingthecmetpathwayinprostatecancercells
AT narulaacharans evodiaminemitigatescellulargrowthandpromotesapoptosisbytargetingthecmetpathwayinprostatecancercells
AT namjoshiojasa evodiaminemitigatescellulargrowthandpromotesapoptosisbytargetingthecmetpathwayinprostatecancercells
AT bloughbrucee evodiaminemitigatescellulargrowthandpromotesapoptosisbytargetingthecmetpathwayinprostatecancercells
AT ahnkwangseok evodiaminemitigatescellulargrowthandpromotesapoptosisbytargetingthecmetpathwayinprostatecancercells